S&P 500   4,631.06 (+1.40%)
DOW   34,810.74 (+0.95%)
QQQ   397.51 (+0.94%)
AAPL   167.69 (+1.45%)
MSFT   335.30 (+1.42%)
FB   326.94 (+0.76%)
GOOGL   2,886.13 (+1.70%)
AMZN   3,532.48 (+0.72%)
TSLA   1,161.90 (+1.50%)
NVDA   329.92 (+0.97%)
BABA   127.85 (+0.25%)
NIO   39.95 (+2.10%)
CGC   10.64 (-0.65%)
AMD   158.60 (+0.15%)
GE   96.18 (+1.25%)
MU   86.77 (+3.30%)
T   22.86 (+0.13%)
F   19.92 (+3.80%)
DIS   148.25 (+2.31%)
ACB   6.39 (-0.47%)
PFE   52.98 (-1.40%)
AMC   34.34 (+1.18%)
BA   198.79 (+0.48%)
S&P 500   4,631.06 (+1.40%)
DOW   34,810.74 (+0.95%)
QQQ   397.51 (+0.94%)
AAPL   167.69 (+1.45%)
MSFT   335.30 (+1.42%)
FB   326.94 (+0.76%)
GOOGL   2,886.13 (+1.70%)
AMZN   3,532.48 (+0.72%)
TSLA   1,161.90 (+1.50%)
NVDA   329.92 (+0.97%)
BABA   127.85 (+0.25%)
NIO   39.95 (+2.10%)
CGC   10.64 (-0.65%)
AMD   158.60 (+0.15%)
GE   96.18 (+1.25%)
MU   86.77 (+3.30%)
T   22.86 (+0.13%)
F   19.92 (+3.80%)
DIS   148.25 (+2.31%)
ACB   6.39 (-0.47%)
PFE   52.98 (-1.40%)
AMC   34.34 (+1.18%)
BA   198.79 (+0.48%)
S&P 500   4,631.06 (+1.40%)
DOW   34,810.74 (+0.95%)
QQQ   397.51 (+0.94%)
AAPL   167.69 (+1.45%)
MSFT   335.30 (+1.42%)
FB   326.94 (+0.76%)
GOOGL   2,886.13 (+1.70%)
AMZN   3,532.48 (+0.72%)
TSLA   1,161.90 (+1.50%)
NVDA   329.92 (+0.97%)
BABA   127.85 (+0.25%)
NIO   39.95 (+2.10%)
CGC   10.64 (-0.65%)
AMD   158.60 (+0.15%)
GE   96.18 (+1.25%)
MU   86.77 (+3.30%)
T   22.86 (+0.13%)
F   19.92 (+3.80%)
DIS   148.25 (+2.31%)
ACB   6.39 (-0.47%)
PFE   52.98 (-1.40%)
AMC   34.34 (+1.18%)
BA   198.79 (+0.48%)
S&P 500   4,631.06 (+1.40%)
DOW   34,810.74 (+0.95%)
QQQ   397.51 (+0.94%)
AAPL   167.69 (+1.45%)
MSFT   335.30 (+1.42%)
FB   326.94 (+0.76%)
GOOGL   2,886.13 (+1.70%)
AMZN   3,532.48 (+0.72%)
TSLA   1,161.90 (+1.50%)
NVDA   329.92 (+0.97%)
BABA   127.85 (+0.25%)
NIO   39.95 (+2.10%)
CGC   10.64 (-0.65%)
AMD   158.60 (+0.15%)
GE   96.18 (+1.25%)
MU   86.77 (+3.30%)
T   22.86 (+0.13%)
F   19.92 (+3.80%)
DIS   148.25 (+2.31%)
ACB   6.39 (-0.47%)
PFE   52.98 (-1.40%)
AMC   34.34 (+1.18%)
BA   198.79 (+0.48%)
NASDAQ:IDRA

Idera Pharmaceuticals Stock Forecast, Price & News

$0.64
-0.01 (-1.67%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.64
$0.64
50-Day Range
$0.64
$1.11
52-Week Range
$0.60
$6.14
Volume
100 shs
Average Volume
1.79 million shs
Market Capitalization
$33.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.62
30 days | 90 days | 365 days | Advanced Chart
Receive IDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Idera Pharmaceuticals logo

About Idera Pharmaceuticals

Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IDRA
Employees
32
Year Founded
1989

Sales & Book Value

Annual Sales
$1.45 million
Book Value
($2.59) per share

Profitability

Net Income
$-112.66 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
50,105,000
Market Cap
$33.80 million
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/07/2022

Social Links


MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

1035th out of 1,390 stocks

Biological Products, Except Diagnostic Industry

159th out of 202 stocks

Analyst Opinion: 3.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions

Is Idera Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Idera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IDRA, but not buy additional shares or sell existing shares.
View analyst ratings for Idera Pharmaceuticals
or view top-rated stocks.

How has Idera Pharmaceuticals' stock price been impacted by Coronavirus?

Idera Pharmaceuticals' stock was trading at $1.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IDRA shares have decreased by 52.8% and is now trading at $0.6510.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Idera Pharmaceuticals?

Idera Pharmaceuticals saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 329,600 shares, a drop of 32.3% from the October 31st total of 486,700 shares. Based on an average daily trading volume, of 492,800 shares, the short-interest ratio is presently 0.7 days. Currently, 0.8% of the shares of the company are short sold.
View Idera Pharmaceuticals' Short Interest
.

When is Idera Pharmaceuticals' next earnings date?

Idera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Idera Pharmaceuticals
.

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) posted its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01.
View Idera Pharmaceuticals' earnings history
.

When did Idera Pharmaceuticals' stock split? How did Idera Pharmaceuticals' stock split work?

Shares of Idera Pharmaceuticals reverse split on the morning of Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for IDRA?

5 Wall Street analysts have issued twelve-month target prices for Idera Pharmaceuticals' shares. Their forecasts range from $1.00 to $2.00. On average, they anticipate Idera Pharmaceuticals' share price to reach $1.50 in the next year. This suggests a possible upside of 130.4% from the stock's current price.
View analysts' price targets for Idera Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the following people:
  • Vin Milano, President, Chief Executive Officer & Director
  • Don Soland, Chief Operating Officer & Senior Vice President
  • John J. Kirby, Chief Financial Officer & Senior Vice President (LinkedIn Profile)
  • Bryant Lim, Secretary, Senior VP & General Counsel
  • Shah Rahimian, Medical Director

What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO?

7 employees have rated Idera Pharmaceuticals CEO Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among Idera Pharmaceuticals' employees.

What other stocks do shareholders of Idera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include (OAS), BioCryst Pharmaceuticals (BCRX), Sorrento Therapeutics (SRNE), Novavax (NVAX), Dynavax Technologies (DVAX), Proteostasis Therapeutics (PTI), Geron (GERN), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO) and Anavex Life Sciences (AVXL).

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Two Sigma Advisers LP (1.51%), Marshall Wace LLP (0.77%), Geode Capital Management LLC (0.71%), Renaissance Technologies LLC (0.51%), Two Sigma Investments LP (0.50%) and Morgan Stanley (0.25%). Company insiders that own Idera Pharmaceuticals stock include Bryant David Lim, Daniel B Soland, Elizabeth Ann Tarka, Invest Corp Pillar, John J Kirby, John J Kirby, Jonathan Michael Yingling, Michael R Dougherty, Robert C Fletcher and Vincent Milano.
View institutional ownership trends for Idera Pharmaceuticals
.

Which major investors are selling Idera Pharmaceuticals stock?

IDRA stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Citadel Advisors LLC, and Jane Street Group LLC. Company insiders that have sold Idera Pharmaceuticals company stock in the last year include Bryant David Lim, Elizabeth Ann Tarka, John J Kirby, and Vincent Milano.
View insider buying and selling activity for Idera Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Idera Pharmaceuticals stock?

IDRA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Geode Capital Management LLC, Morgan Stanley, and Goldman Sachs Group Inc.. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Daniel B Soland, Invest Corp Pillar, and Michael R Dougherty.
View insider buying and selling activity for Idera Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $0.65.

How much money does Idera Pharmaceuticals make?

Idera Pharmaceuticals has a market capitalization of $34.37 million and generates $1.45 million in revenue each year. The biotechnology company earns $-112.66 million in net income (profit) each year or ($2.51) on an earnings per share basis.

How many employees does Idera Pharmaceuticals have?

Idera Pharmaceuticals employs 32 workers across the globe.

When was Idera Pharmaceuticals founded?

Idera Pharmaceuticals was founded in 1989.

What is Idera Pharmaceuticals' official website?

The official website for Idera Pharmaceuticals is www.iderapharma.com.

Where are Idera Pharmaceuticals' headquarters?

Idera Pharmaceuticals is headquartered at 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at (484) 348-1600, via email at [email protected], or via fax at 617-679-5592.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.